Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of “Hold” by Brokerages

Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have been assigned an average rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $32.00.

Several brokerages have weighed in on FLGT. Raymond James Financial reiterated an “outperform” rating and issued a $36.00 target price on shares of Fulgent Genetics in a report on Friday, November 14th. Zacks Research cut shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Piper Sandler raised their target price on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a research report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Fulgent Genetics from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th.

Institutional Investors Weigh In On Fulgent Genetics

Hedge funds have recently made changes to their positions in the stock. Amundi grew its stake in Fulgent Genetics by 289.2% in the first quarter. Amundi now owns 34,316 shares of the company’s stock valued at $583,000 after purchasing an additional 25,500 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Fulgent Genetics by 28.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 202,820 shares of the company’s stock worth $3,428,000 after buying an additional 45,279 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Fulgent Genetics by 22.2% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 305,180 shares of the company’s stock worth $6,067,000 after acquiring an additional 55,521 shares in the last quarter. Campbell & CO Investment Adviser LLC lifted its position in Fulgent Genetics by 51.7% during the second quarter. Campbell & CO Investment Adviser LLC now owns 27,061 shares of the company’s stock valued at $538,000 after acquiring an additional 9,217 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in Fulgent Genetics by 38.7% during the second quarter. Acadian Asset Management LLC now owns 1,117,917 shares of the company’s stock valued at $22,208,000 after acquiring an additional 311,976 shares during the last quarter. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Fulgent Genetics Price Performance

Shares of FLGT stock opened at $13.79 on Wednesday. The company has a market capitalization of $430.66 million, a P/E ratio of -7.04 and a beta of 0.94. The company’s 50-day simple moving average is $25.13 and its two-hundred day simple moving average is $24.77. Fulgent Genetics has a one year low of $13.46 and a one year high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.14. Fulgent Genetics had a negative net margin of 18.75% and a negative return on equity of 2.22%. The firm had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. On average, research analysts expect that Fulgent Genetics will post -0.85 EPS for the current fiscal year.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.